CDA | Evidence Driven
CDA | Evidence Driven

Zytiga for Metastatic Castration Resistant Prostate Cancer - Details

Details

Files
Generic Name:
Abiraterone acetate
Project Status:
Complete
Therapeutic Area:
Metastatic Castration Resistant Prostate Cancer
Manufacturer:
Janssen Inc.
Brand Name:
Zytiga
Project Line:
Reimbursement Review
Project Number:
PC0028-000
Performance Metric:
N/A — Predated performance metrics
Strength:
250 mg tablet
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Resistant Prostate Cancer
Funding Request:
For asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients after failure of ADT (have not received prior chemotherapy)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
No
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Abiraterone Acetate (Zytiga) for mCRPC - pERC Final Recommendation Final Recommendation October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) for mCRPC - Final Clinical Guidance Report Guidance Reports October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) for mCRPC - Final Economic Guidance Report Guidance Reports October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) for mCRPC - pERC Initial Recommendation Initial Recommendation October 3, 2013 View PDF
Abiraterone Acetate (Zytiga) - PAG Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) - Manufacturer (Janssen) Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (CCSN) Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (CCSN) COI Declarations Feedback October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (PCC) Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Abiraterone Acetate (Zytiga) - Patient Advocacy Group (PCC) COI Declarations Feedback October 22, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 6, 2013